Your browser doesn't support javascript.
loading
Survival and Incidence Patterns of Pancreatic Neuroendocrine Tumors Over the Last 2 Decades: A SEER Database Analysis.
Sonbol, Mohamad Bassam; Mazza, Gina L; Mi, Lanyu; Oliver, Thomas; Starr, Jason; Gudmundsdottir, Hallbera; Cleary, Sean P; Hobday, Timothy; Halfdanarson, Thorvardur R.
Afiliación
  • Sonbol MB; Mayo Clinic Cancer Center, Phoenix, AZ, USA.
  • Mazza GL; Clinical Trials and Biostatistics, Mayo Clinic, Phoenix, AZ, USA.
  • Mi L; Clinical Trials and Biostatistics, Mayo Clinic, Phoenix, AZ, USA.
  • Oliver T; Mayo Clinic Cancer Center, Phoenix, AZ, USA.
  • Starr J; Mayo Clinic Cancer Center, Phoenix, FL, USA.
  • Gudmundsdottir H; Mayo Clinic Cancer Center, Rochester, MN, USA.
  • Cleary SP; Mayo Clinic Cancer Center, Rochester, MN, USA.
  • Hobday T; Mayo Clinic Cancer Center, Rochester, MN, USA.
  • Halfdanarson TR; Mayo Clinic Cancer Center, Rochester, MN, USA.
Oncologist ; 27(7): 573-578, 2022 07 05.
Article en En | MEDLINE | ID: mdl-35348774
BACKGROUND: Pancreatic neuroendocrine tumors (pNETs) are rare cancers with outcomes determined by multiple factors including grade, stage, and clinical presentation. In this study, we aimed to determine the prognosis of patients with pNETs using a large population-based database. MATERIALS AND METHODS: In this population-based study, we identified patients with pNETs from the SEER 18 registry (2000-2016) using a combination of ICD-O-3 and histology codes. We calculated age-adjusted incidence rates using SEER*Stat 8.3.5. In addition, we analyzed overall survival (OS) using the Kaplan-Meier method, and investigated prognostic factors using a multivariable Cox proportional hazards model. RESULTS: A total of 8944 pNETs patients were identified. Annual incidence rates increased from 0.27 to 1.00 per 100 000. This was largely explained by an increase in number of patients diagnosed with localized disease in more recent years (2012-2016). Median OS was 68 months (95% CI [64, 73]) and 5-year OS rates in localized, regional, and metastatic disease were 83%, 67%, and 28%, respectively. There was a significant improvement in OS for patients diagnosed between 2009 and 2016 (median OS 85 months) compared with those diagnosed between 2000 and 2008 (median OS 46 months) (HR 0.66; 95% CI [0.62, 0.70]). This improvement in OS was consistent across all stages. CONCLUSIONS AND RELEVANCE: This study shows a steady increase pNETs incidence with notable stage migration to earlier stages in recent years. This increase in incidence is accompanied by a significant improvement in survival across different disease stages.
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias Pancreáticas / Tumores Neuroendocrinos / Tumores Neuroectodérmicos Primitivos Tipo de estudio: Incidence_studies / Prognostic_studies / Risk_factors_studies Límite: Humans Idioma: En Revista: Oncologist Asunto de la revista: NEOPLASIAS Año: 2022 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Reino Unido
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias Pancreáticas / Tumores Neuroendocrinos / Tumores Neuroectodérmicos Primitivos Tipo de estudio: Incidence_studies / Prognostic_studies / Risk_factors_studies Límite: Humans Idioma: En Revista: Oncologist Asunto de la revista: NEOPLASIAS Año: 2022 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Reino Unido